Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Quandt, Dagmar ^a   Jasinski Bergner, Simon ^a   Müller, Ulrike ^a   Schulze, Bianca ^a   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Anti tumor response; B7 H molecules; Costimulation; Renal cell carcinoma; T cells

Indexed keywords

ALPHA INTERFERON; B7 H3 PROTEIN; BETA INTERFERON; CD40 ANTIGEN; HLA ANTIGEN CLASS 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT INTERLEUKIN 4; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; STAT6 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; INTERLEUKIN 4; PRIMER DNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CARCINOMA CELL; CD8+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; REPORTER GENE; TRANSCRIPTION REGULATION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; UPREGULATION; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; KIDNEY TUMOR; NUCLEOTIDE SEQUENCE; PATHOLOGY; T LYMPHOCYTE;

ANTIGENS, CD274; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; HUMANS; INTERLEUKIN-4; KIDNEY NEOPLASMS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903792211     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-151     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Organization WH: mortality database http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 07/05/2013, Organization WH: mortality database.
3. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012, 23(8):35-40.
4. Seliger B, Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012, 61:1327-1341. 10.1007/s00262-012-1293-6, 22695874.
5. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008, 111:3635-3643. 10.1182/blood-2007-11-123141, 2275025, 18223165.
6. Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011, 68:3531-3539. 10.1007/s00018-011-0802-7, 21877119.
7. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548. 10.1146/annurev.immunol.23.021704.115611, 15771580.
8. Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013, 15:98-104. 10.1007/s11912-012-0284-2, 23263823.
9. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66:3381-3385. 10.1158/0008-5472.CAN-05-4303, 16585157.
10. Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M, Junker K. A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J Urol 2011, 186:289-294. 10.1016/j.juro.2011.03.033, 21600596.
11. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009, 20:43-59. 10.1016/j.cytogfr.2008.11.006, 19038572.
12. Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wuest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jager D, Scott AM, Ritter G, Old LJ, Renner C. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer 2009, 125:115-123. 10.1002/ijc.24359, 19384924.
13. Hoon DS, Okun E, Banez M, Irie RF, Morton DL. Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res 1991, 51:5687-5693.
14. Ikemoto S, Narita K, Yoshida N, Wada S, Kishimoto T, Sugimura K, Nakatani T. Effects of tumor necrosis factor alpha in renal cell carcinoma. Oncol Rep 2003, 10:1947-1955.
15. Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther 2013, 13:911-925. 10.1517/14712598.2013.778970, 23586712.
16. Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol 1994, 15:147-153. 10.1097/00002371-199402000-00009, 8136948.
17. Motzer RJ, Russo P, Nanus DM, Berg WJ. Renal cell carcinoma. Curr Probl Cancer 1997, 21:185-232. 10.1016/S0147-0272(97)80007-4, 9285186.
18. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest oncology group study. J Immunother 2002, 25:352-358. 10.1097/00002371-200207000-00007, 12142558.
19. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006, 119:317-327. 10.1002/ijc.21775, 16482562.
20. Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, Shinya E, Takahashi H, Tamada K, Chen L, Dan K, Ogata K. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 2010, 116:1124-1131. 10.1182/blood-2009-12-255125, 3375140, 20472834.
21. Quandt D, Fiedler E, Boettcher D, Marsch W, Seliger B. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res 2011, 17:3100-3111. 10.1158/1078-0432.CCR-10-2268, 21378130.
22. Wulfanger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B. Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. Int J Cancer 2013, 133:2522-2532.
23. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem 2010, 285:30419-30426. 10.1074/jbc.M109.094284, 2945534, 20663889.
24. Chen Y, Zhang J, Guo G, Ruan Z, Jiang M, Wu S, Guo S, Fei L, Tang Y, Yang C, Jia Z, Wu Y. Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9. Mol Immunol 2009, 46:375-383. 10.1016/j.molimm.2008.10.026, 19081139.
25. Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Muller A, Hiebl B, Holzhausen HJ, Seliger B. HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol Cancer Res 2013, 11:1462-1477. 10.1158/1541-7786.MCR-13-0125, 24025972.
26. Falkensammer C, Johrer K, Gander H, Ramoner R, Putz T, Rahm A, Greil R, Bartsch G, Thurnher M. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. Cancer Immunol Immunother 2006, 55:1228-1237. 10.1007/s00262-006-0122-1, 16810557.
27. Waddick KG, Uckun FM. Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Biochem Pharmacol 1998, 56:1411-1426. 10.1016/S0006-2952(98)00211-1, 9827573.
28. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
29. Kochli C, Wendland T, Frutig K, Grunow R, Merlin S, Pichler WJ. CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Immunol Lett 1999, 65:197-201. 10.1016/S0165-2478(98)00107-2, 10065743.
30. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122. 10.1016/j.immuni.2007.05.016, 2707944, 17629517.
31. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008, 14:5150-5157. 10.1158/1078-0432.CCR-08-0536, 2789387, 18694993.
32. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006, 103:10391-10396. 10.1073/pnas.0600937103, 1502468, 16798883.
33. Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann A, Melms A, Tolosa E, Weller M, Wiendl H. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia 2003, 44:296-301. 10.1002/glia.10291, 14603470.
34. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL. Expression of ICOS on human melanoma-infiltrating CD4 + CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008, 180:2967-2980. 10.4049/jimmunol.180.5.2967, 18292519.
35. Wallin JJ, Liang L, Bakardjiev A, Sha WC. Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J Immunol 2001, 167:132-139. 10.4049/jimmunol.167.1.132, 11418641.
36. Mizutani Y, Bonavida B, Nio Y, Yoshida O. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol 1994, 151:1697-1702.
37. Obiri NI, Puri RK. Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells. Oncol Res 1994, 6:419-427.
38. Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Movassagh M, Lu W, Mills IG, Neal DE, Burge J, Vandenebeele P, Pober JS, Bradley JR. Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol 2010, 177:943-954. 10.2353/ajpath.2010.091218, 2913335, 20566746.
39. Varricchio F, Obiri NI, Haas GP, Puri RK. Immunostaining of interleukin-4 receptor on human renal cell carcinoma. Lymphokine Cytokine Res 1993, 12:465-469.
40. Ikemoto S, Yoshida N, Narita K, Wada S, Kishimoto T, Sugimura K, Nakatani T. Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep 2003, 10:1843-1849.
41. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2013, 62:1757-1768. 10.1007/s00262-013-1487-6, 24132754.
42. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998, 10:588-594. 10.1016/S0952-7915(98)80228-8, 9794842.
43. Zhu J, Ju X, Yan F, Qin C, Wang M, Ding Q, Zhang Z, Yin C. Association of IL-4 -590 T>C polymorphism and risk of renal cell carcinoma in a Chinese population. Int J Immunogenet 2010, 37:459-465. 10.1111/j.1744-313X.2010.00948.x, 20618516.
44. Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 2007, 25:845-851. 10.1200/JCO.2006.07.8154, 17327605.
45. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006, 203:871-881. 10.1084/jem.20050930, 2118300, 16606666.
46. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999, 11:423-432. 10.1016/S1074-7613(00)80117-X, 10549624.
47. Youngnak-Piboonratanakit P, Tsushima F, Otsuki N, Igarashi H, Omura K, Azuma M. Expression and regulation of human CD275 on endothelial cells in healthy and inflamed mucosal tissues. Scand J Immunol 2006, 63:191-198. 10.1111/j.1365-3083.2006.01726.x, 16499572.
48. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002, 169:3581-3588. 10.4049/jimmunol.169.7.3581, 12244148.
49. Makgoba MW, Sanders ME, Shaw S. The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition. Immunol Today 1989, 10:417-422. 10.1016/0167-5699(89)90039-X, 2482743.
50. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007, 13:1757-1761. 10.1158/1078-0432.CCR-06-2599, 17363529.
51. Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic O, Steinberger P. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 2006, 36:1104-1113. 10.1002/eji.200535344, 2975063, 16598819.
52. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268. 10.1038/85330, 11224527.
53. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 2003, 100:5336-5341. 10.1073/pnas.0931259100, 154346, 12697896.
54. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998, 10:573-580. 10.1016/S0952-7915(98)80226-4, 9794839.